Technology Revolutionizing Energy Mix but Policy Failing to Keep Pace – DNV GL Energy Transition Outlook Report
11.9.2019 02:01:00 EEST | Business Wire | Press release
A technology-driven energy transition of staggering scale and speed will lead to a rapid decarbonization of the energy mix, with almost half our energy needs met by renewables by 2050, according to a new report. Plunging technology costs and market forces are driving the transition, but without bold policy intervention we will fall well short of the Paris climate goals. These are some of the findings of the third edition of the Energy Transition Outlook (ETO), which, owing to DNV GL’s independence and technical expertise, has become a respected voice in forecasting our energy future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910006000/en/
Technology Revolutionizing Energy Mix but Policy Failing to Keep Pace – DNV GL Energy Transition Outlook Report (Graphic: Business Wire)
The speed of the transition is demonstrated by a series of landmarks in the coming decade. Oil will peak in mid 2020s, capital expenditure (CAPEX) on grids and renewables will exceed fossil CAPEX by 2025, natural gas will overtake oil as the single largest energy source in 2026 and in 2030 the amount of energy produced will start to decline even in a world of growing GDP.
Electrification will transform how energy is produced and consumed. By midcentury, 40% of final energy demand will be met by electricity (up from 19% in 2017), 63% of which will be generated by solar PV and wind. Electrification is also having a dramatic effect on road transport and by 2032 half of new car sales globally will be electric. The intrinsic efficiency of electric engines means that despite a 75% expansion of the global vehicle fleet by 2050, road transportation will use less energy in 2050 than it does today.
“Existing technology can deliver the future we desire – including meeting the 1.5°C target set out in the Paris Agreement. So far, support for the energy transition has been too sporadic. For example, German, Japanese and Chinese support for the solar industry has been vital in transforming its energy mix and Norway’s and China’s uptake of EVs has been rapid because of government support. We need widespread policy supporting emerging technologies, and continuing the support in the build-up phase to accelerate the energy transition” said Remi Eriksen, Group President and CEO of DNV GL.
The technology exists to meet the Paris target, but policies must be put in place that promote greater energy efficiency, more renewables and industrial scale carbon capture and storage. DNV GL has proposed ten measures that could be implemented to limit global warming. These actions include; $1.5 trillion of annual investment in expanding and reinforcing energy grids, an 8-fold increase in renewable energy production by 2030 and a 50-fold increase in manufacturing of batteries for the 50 million electric vehicles needed per year, also by 2030. On the current path, CO2 emissions will peak in 2025 and will be about half the current level by mid-century, indicating a warming of 2.4 degrees by the end of the century.
Policy makers can be emboldened by the affordability of the energy transition. Global expenditure on energy is currently 3.6% of GDP but that will fall to 1.9% by 2050. This is due to a decline in spending on fossil fuels, and the rise of low-cost, efficient electrification that leads to operating savings which more than offset ongoing, substantial high CAPEX on grids. This is reflected in declining energy intensity – the amount of energy required per unit of GDP – which will improve at 2.4% per year through to 2050. Going forward, energy intensity declines faster than the global economy grows, which leads to a peak in world energy demand by 2030 – at that point humanity will start using less energy.
--ENDS--
Download data from the ETO model
About DNV GL
DNV GL is a global quality assurance and risk management company. Driven by our purpose of safeguarding life, property and the environment, we enable our customers to advance the safety and sustainability of their business. Operating in more than 100 countries, our professionals are dedicated to helping customers in the maritime, oil & gas, power and renewables and other industries to make the world safer, smarter and greener.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006000/en/
Contact information
Media Relations Manager
Peter Lovegrove
peter.lovegrove@dnvgl.com
+47 40904294
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
